Prometheon Pharma, LLC is a biotechnology startup based in the United States, founded in 2011. The company has developed a transdermal platform technology called Topicon™, which is tailored for creating drug patch products facilitating passive delivery across the skin of large molecule drugs. Prometheon's TruePatch™ products eliminate the need for microneedles and offer a convenient, painless, and truly needle-free application. The startup aims to introduce innovative products such as a basal insulin TruePatch™ for diabetes treatment and a novel class of anti-obesity drugs. Collaborating with other pharma companies to address drug delivery challenges, Prometheon is committed to finding scalable biotechnology solutions for complex health and social issues. Their industry-sponsored study on Topicon™ Cyclosporin A topical therapy shows promise in treating inflammatory skin diseases. With the last recorded investment being a $1.13M Convertible Note in April 2016, Prometheon Pharma is positioning itself as a pioneering player in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | $1.13M | - | 15 Apr 2016 |
No recent news or press coverage available for Prometheon Pharma, LLC.
We care about your data, and we'd love to use cookies make your experience better.
